Mortality (calculated instead of overall survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality (instead of overall survival) compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).
1 finding from 1 review
Overall survival · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).
1 finding from 1 review
Overall survival · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
Overall survival not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival: Median length of · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab probably leads to lower overall survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).
1 finding from 1 review
Overall survival ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival · people diagnosed with chemotherapy‐induced anemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to lower overall Survival ‐ Bortezomib versus no bortezomib (same background… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Overall Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to lower overall Survival ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival · individuals with HL
1 finding from 1 review
Intervention not reported
Overall survival · Adult patients with follicular lymphoma
The intervention showed no clear difference in overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival ( · people with relapsed or refractory DLBCL
1 finding from 1 review
Overall survival (number of deaths at · Patients with treating MF
Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival [range of median · patients with APL in first complete remission
The intervention may leads to lower overall survival [range of median (low certainty).
1 finding from 1 review
no estimate extracted
892 participants
Low
Intervention not reported
Overall survival [range of median · patients with APL in first complete remission
The intervention probably leads to lower overall survival [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
632 participants
Moderate
Intervention not reported
Overall survival [range of median · patients with APL in first complete remission
The intervention probably leads to lower overall survival [range of median (moderate certainty).
1 finding from 1 review
no estimate extracted
1033 participants
Moderate
Intervention not reported
Mortality (instead of overall survival)[2] · People with AML in first complete remission
The intervention showed no clear difference in mortality (instead of overall survival)[2] (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (calculated instead of overall survival)
The intervention showed no clear difference in mortality (calculated instead of overall survival) (moderate certainty).
1 finding from 1 review